Monica Verrico
A5015919378- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- Neuroblastoma Research and Treatments
- Cervical Cancer and HPV Research
- Pancreatic and Hepatic Oncology Research
- Neutropenia and Cancer Infections
- Gallbladder and Bile Duct Disorders
- Colorectal Cancer Treatments and Studies
- Cancer Risks and Factors
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Reproductive Biology and Fertility
- Intraperitoneal and Appendiceal Malignancies
- Pituitary Gland Disorders and Treatments
- Lung Cancer Treatments and Mutations
- Gyrotron and Vacuum Electronics Research
- Cancer, Hypoxia, and Metabolism
- Pediatric Hepatobiliary Diseases and Treatments
- Hepatocellular Carcinoma Treatment and Prognosis
- Gestational Trophoblastic Disease Studies
- Genital Health and Disease
- Breast Lesions and Carcinomas
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
Policlinico Umberto I
2019-2025
IRCCS Istituto Auxologico Italiano
2024
Istituti di Ricovero e Cura a Carattere Scientifico
2022-2024
Sapienza University of Rome
2013-2024
Ospedale Santa Maria Goretti
2012-2022
Istituto Neurologico Mediterraneo
2022
Background Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its long-term efficacy remains sparse. Methods This study assessed 5-year outcomes of first-line pembrolizumab in a large, multicenter, cohort patients NSCLC and PD-L1 TPS≥50%, referred to as Pembro-real 5Y. Individual patient-level (IPD) from the experimental arm...
Well-differentiated lung neuroendocrine tumors (Lu-NET) are classified as typical (TC) and atypical (AC) carcinoids, based on mitotic counts necrosis. However, prognostic factors, other than tumor node metastasis (TNM) stage the histopathological diagnosis, still lacking. The current study is aimed to identify potential factors better stratify NET, thus, improving patients' treatment strategy follow-up.A multicentric retrospective study, including 300 Lung all surgically removed, from...
Neuroendocrine tumors (NETs) early diagnosis is a clinical challenge that require deep understanding of molecular and genetic features this heterogeneous group neoplasms. However, few biomarkers exist to aid predict prognosis treatment response. In the oncological field, tumor-educated platelets (TEPs) have been implicated as central players in systemic local responses tumor growth, thereby altering specific RNA profile. Although TEPs found be enriched RNAs, studies investigated potential...
Neutropenia is a common toxicity in patients receiving myelosuppressive chemotherapy. In this prospective pilot study, we compared the efficacy and safety profiles of pegfilgrastim administered subcutaneously once per cycle lenograstim daily six times cycle, for primary neutropenia prophylaxis women with breast cancer adjuvant anthracycline-based chemotherapy.Twenty were enrolled. All received epirubicin 100 mg/m(2) 5-fluorouracil 500 cyclophosphamide on day 1 every 21 days thereafter,...
Abstract Purpose Thyroid transcription factor‐1 (TTF‐1) assessed by immunohistochemistry (IHC) is a specific biomarker for lung adenocarcinoma, and commonly used to confirm the pulmonary origin of neuroendocrine tumours (NET). The majority available data suggest that TTF-1 favourable prognostic adenocarcinomas, whereas its role more conflicting NET. main aim this multicenter retrospective study was investigate potentially relevant associations between clinical pathological features...
Head and neck paragangliomas are the most common clinical features of familial paraganglioma syndrome type 1 caused by succinate dehydrogenase complex subunit D (SDHD) mutation. The management this is still unclear. In study we propose a diagnostic algorithm for SDHD mutation carriers based on our family case series literature review. After genetic diagnosis, first evaluation should include biochemical examination whole-body imaging. lesion detection, nuclear medicine required staging tumor...
Vetrano, G; Lombardi, Leone, G Di; Parisi, A; Scardamaglia, P; Pate, Verrico, M; Corosu, R Author Information
Carcinoma ex pleomorphic adenoma is a rare tumor arising from the salivary glands that spreads through direct extension, lymphatic vessels, and, rarely, hematogenously. When distant metastases have been found, they reported mainly in lung. We present an unusual case of carcinoma parotid gland with splenic metastases. The patient presented primary and he underwent total parotidectomy laterocervical lymphadenectomy ipsilateral adjuvant radiation therapy to right area. One year later, showed...
The lung large-cell neuroendocrine carcinoma (LCNEC) is a very rare aggressive tumor with high propensity to metastasize and poor prognosis. We report an atypical presentation of LCNEC was diagnosed from metastatic nodule on the breast.Our patient 59-years-old woman that presented in March 2014 nonproductive cough. A CT scan showed multiple brain, lung, adrenal gland liver secondary lesions; moreover, it revealed breast right near chest measuring 1.8 cm. lesions were biopsied their histology...